AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind
Though momentum is building for IDO/PD-1 combos, it's still early days for new immunotherapy programs. Clinicians and investors weigh in on the latest data from the American Association for Cancer Research meeting and the state of the immuno-oncology field.
You may also be interested in...
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.
FDA's approval of Merck's Keytruda/chemo combo based on Phase II data secures the company's position in the prized first-line lung cancer indication, but Phase III readouts from other combination trials are right around the corner.
NewLink is hoping FDA will accept its plans to run one Phase III registrational study of its IDO pathway inhibitor indoximod with an anti-PD-1 agent in frontline melanoma; Incyte updates its Phase III plans for epacadostat.